ABOUT BAPA

Our Mission

Advocate – Educate – Communicate

We strive to organize Bangladeshi-American Pharmacists in a strong and professional platform so they can be more successful in their career and have a fulfilling experience in this country. We work to get the members involved in the socio-political process that determines their future. We hope to motivate everyone to contribute their time and talent to the betterment of the pharmacy profession here at home and in Bangladesh.

Specifically, the purpose of the organization is to foster cooperation and collaboration among Bangladeshi pharmacists residing in North America; to build and maintain relations with other pharmacists’ associations in North America, to support the profession of pharmacy in Bangladesh and in North America; to support and encourage the development of Pharmaceutical Science in Bangladesh; to develop and conduct programs for maintaining and improving the professional standards; to promote welfare of members’ families in case of need; to protect the professional interests of members of the Association.

BAPA Logo

Pharmaceutical News

  • Researchers call for worldwide biosurveillance network to protect from diseases
    on July 9, 2020 at 10:00 am

    The emergence of COVID-19 is a powerful reminder of how unchecked wildlife trade can lead to the spillover spread of viruses between wildlife and humans. Understanding that wholesale bans on trade can affect community livelihoods and food security, the pandemic underscores the need for widespread pathogen screening and monitoring to better understand, predict and contain outbreaks in wildlife and humans.

  • New study supports remdesivir as COVID-19 treatment
    on July 9, 2020 at 8:00 am

    The news about remdesivir, the investigational anti-viral drug that has shown early promise in the fight against COVID-19, keeps getting better. This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus.

  • Neutralizing antibodies in the battle against COVID-19
    on July 8, 2020 at 8:00 am

    An important line of defence in the fight against the new corona virus SARS-CoV-2 is the formation of neutralising antibodies. These can eliminate the intruders and have great potential to be used for prevention and treatment of SARS-CoV-2 infection. A team of researchers led by Prof. Florian Klein (Cologne University Hospital) and the German Center for Infection Research (DZIF) has further elucidated how these antibodies develop and has isolated potent SARS-CoV-2 neutralizing antibodies.

  • Remdesivir can save more lives where ICUs are overwhelmed
    on July 7, 2020 at 10:00 am

    Amid news that the United States has bought up virtually the entire global supply of remdesivir, a new Boston University School of Public Health (BUSPH) study outlines how the drug could save lives in countries with less hospital capacity, such as South Africa, where COVID-19 is beginning to overwhelm intensive care units (ICUs).

  • GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine
    on July 7, 2020 at 8:00 am

    GSK and Medicago announced a collaboration to develop and evaluate a COVID-19 candidate vaccine combining Medicago's recombinant Coronavirus Virus-Like Particles (CoVLP) with GSK's pandemic adjuvant system. CoVLPs mimic the structure of the virus responsible for COVID-19 disease, allowing them to be recognised by the immune system.